Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Spruce Biosciences, Inc. (SPRB : OTC)
 
 • Company Description   
Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy which are in clinical stage. Spruce Biosciences Inc. is based in Daly City, California.

Number of Employees: 21

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.07 Daily Weekly Monthly
20 Day Moving Average: 282,588 shares
Shares Outstanding: 42.23 (millions)
Market Capitalization: $3.06 (millions)
Beta: 2.40
52 Week High: $0.61
52 Week Low: $0.06
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 11.39% 5.35%
12 Week -75.47% -79.42%
Year To Date -82.76% -83.85%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
611 GATEWAY BOULEVARD SUITE 740
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 415-655-4168
fax: -
investors@sprucebio.com http://www.sprucebiosciences.com
 
 • General Corporate Information   
Officers
Javier Szwarcberg - Chief Executive Officer
Michael Grey - Executive Chairman
Samir Gharib - President and Chief Financial Officer
Tiba Aynechi - Director
Percival Barretto-Ko - Director

Peer Information
Spruce Biosciences, Inc. (CORR.)
Spruce Biosciences, Inc. (RSPI)
Spruce Biosciences, Inc. (CGXP)
Spruce Biosciences, Inc. (BGEN)
Spruce Biosciences, Inc. (GTBP)
Spruce Biosciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 85209E109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/11/25
Share - Related Items
Shares Outstanding: 42.23
Most Recent Split Date: (:1)
Beta: 2.40
Market Capitalization: $3.06 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.87 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.20
Price/Cash Flow: -
Price / Sales: 0.62
EPS Growth
vs. Year Ago Period: -14.29%
vs. Previous Quarter: 43.86%
Sales Growth
vs. Year Ago Period: -75.86%
vs. Previous Quarter: 15.78%
ROE
06/30/25 - -
03/31/25 - -143.15
12/31/24 - -102.86
ROA
06/30/25 - -
03/31/25 - -101.99
12/31/24 - -77.60
Current Ratio
06/30/25 - -
03/31/25 - 1.95
12/31/24 - 2.90
Quick Ratio
06/30/25 - -
03/31/25 - 1.95
12/31/24 - 2.90
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -1,079.94
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -1,079.94
Pre-Tax Margin
06/30/25 - -
03/31/25 - -1,906.22
12/31/24 - -1,079.94
Book Value
06/30/25 - -
03/31/25 - 0.36
12/31/24 - 0.70
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.43
 

Powered by Zacks Investment Research ©